





PHARMACEUTICAL 2020



Mirati Therapeutics Inc.
Rank 76 of 358

The relative strengths and weaknesses of Mirati Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirati Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 116% points. The greatest weakness of Mirati Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 184%, being 148% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	424,407
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	48,906
Liabilities, Non-Current	0
Other Assets	6,017
Other Compr. Net Income	410
Other Expenses	0
Other Liabilities	999
Other Net Income	8,848
Other Revenues	3,335
Property and Equipment	1,776
Research and Development	182,866
Selling, General and Administrative Expense	42,573

Output Variable	Value in 1000 USD
Assets	432,200
Liabilities	49,905
Expenses	225,439
Revenues	3,335
Stockholders Equity	382,295
Net Income	-213,256
Comprehensive Net Income	-213,051
Economic Capital Ratio	184%